Vyome Holdings, Inc. (HIND)
NASDAQ:HIND
Want to see HIND full AI Analyst Report?
Top Page
Vyome Holdings
(NASDAQ:HIND)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-63.10% Downside)
Action:ReiteratedDate:04/30/26
The score is held down primarily by weak financial performance (sharp revenue decline, heavy losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate developments provide some support, but valuation is not clearly attractive due to losses and no dividend data.
Positive Factors
Phase 2 clinical data (VT-1953)
Positive Phase 2 investigator-initiated results materially de-risk VT-1953 as a treatment for malignant fungating wounds. Efficacy, tolerability and patient-reported benefit create a credible path for further development, potential licensing or partnership and durable commercial optionality in an underserved niche.
Negative Factors
Revenue collapse in 2025
A dramatic revenue decline erodes the company’s commercial base and undermines internal funding for R&D and operations. Such structural revenue deterioration increases dependency on external financing, weakens bargaining power with partners, and raises execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 2 clinical data (VT-1953)
Positive Phase 2 investigator-initiated results materially de-risk VT-1953 as a treatment for malignant fungating wounds. Efficacy, tolerability and patient-reported benefit create a credible path for further development, potential licensing or partnership and durable commercial optionality in an underserved niche.
Read all positive factors
Vyome Holdings (HIND) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.67M
Dividend YieldN/A
Average Volume (3M)28.88K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-69.70%
EPS GrowthN/A
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-29.21
Shares Outstanding7,018,528
10 Day Avg. Volume19,649
30 Day Avg. Volume28,879
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-2.49
Forecast
1Y Price Target
$11.50Price Target Upside112.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Vyome Holdings Business Overview & Revenue Model
Company Description
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey....
Vyome Holdings Earnings Call Summary
Earnings Call Date:Nov 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 26, 2026
Earnings Call Sentiment Positive
The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.Positive Updates
Revenue Growth
Revenue increased by 16.6% in the third quarter over the second quarter and 6.4% over the third quarter of last year.
Negative Updates
Revenue Contraction
Revenue for the 9 months ended September 30, 2024, contracted by 7% or $500,000 compared to the same period in 2023, primarily due to GLP-1 pharmaceutical weight loss alternatives.
Read all updates
Q3-2024 Updates
Positive
Negative
Revenue Growth
Revenue increased by 16.6% in the third quarter over the second quarter and 6.4% over the third quarter of last year.
Read all positive updates
Company Guidance
During the third quarter of 2024, ReShape Lifesciences demonstrated significant financial and operational improvements. Revenue increased by 16.6% compared to the previous quarter and 6.4% year-over-year, marking the third consecutive quarter of growth. The company achieved a gross profit margin of 62.8% for the quarter, with a cumulative margin of 60.3% for the first nine months. Operating expenses were reduced by over 40% compared to the same period last year, and total operating costs for the first nine months were down by 41%. ReShape also reported a non-GAAP adjusted EBITDA of $1.6 million for the quarter, an improvement from a $2.9 million loss in the prior year. In addition, the company secured a supplementary NIH grant of approximately $241,000, bringing total NIH funding to $1.15 million. The company also received approval for its Lap-Band 2.0 FLEX from Health Canada, further expanding its market opportunities.Vyome Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 319.71K | 8.01M | 8.68M | 11.24M | 13.60M |
| Gross Profit | 206.79K | 5.06M | 5.55M | 6.80M | 8.35M |
| EBITDA | -2.74M | -6.65M | -11.18M | -44.33M | -60.62M |
| Net Income | -10.26M | -7.13M | -11.39M | -46.21M | -63.15M |
Balance Sheet | |||||
| Total Assets | 6.50M | 4.79M | 10.73M | 11.27M | 52.53M |
| Cash, Cash Equivalents and Short-Term Investments | 4.98M | 693.00K | 4.56M | 3.96M | 22.77M |
| Total Debt | 31.26K | 967.00K | 262.00K | 171.00K | 279.00K |
| Total Liabilities | 2.74M | 5.05M | 4.06M | 7.60M | 8.20M |
| Stockholders Equity | 2.44M | -253.00K | 6.66M | 3.66M | 44.33M |
Cash Flow | |||||
| Free Cash Flow | -3.75M | -4.43M | -17.00M | -22.03M | -15.73M |
| Operating Cash Flow | -3.75M | -4.43M | -16.96M | -21.90M | -15.38M |
| Investing Cash Flow | 0.00 | 0.00 | -10.00K | -92.00K | 1.85M |
| Financing Cash Flow | 8.65M | 677.00K | 17.57M | 3.13M | 33.30M |
Vyome Holdings Technical Analysis
Negative
5.42
Price Trends
2.51
Negative
3.13
Negative
5.48
Negative
Market Momentum
-0.08
Negative
44.63
Neutral
49.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIND, the sentiment is Negative. The current price of 5.42 is above the 20-day moving average (MA) of 2.21, above the 50-day MA of 2.51, and below the 200-day MA of 5.48, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 44.63 is Neutral, neither overbought nor oversold. The STOCH value of 49.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIND.
Vyome Holdings Risk Analysis
Vyome Holdings disclosed 42 risk factors in its most recent earnings report. Vyome Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vyome Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $25.96M | -120.91 | 9999.00% | ― | -44.57% | 55.97% | |
54 Neutral | $125.21M | 0.05 | -104.96% | ― | 1057.12% | 88.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $14.67M | -4.15 | -364.96% | ― | -69.70% | ― | |
42 Neutral | $9.97M | -1.21 | -204.04% | ― | -64.74% | 71.67% | |
40 Underperform | $6.50M | -1.29 | -220.42% | ― | ― | 51.71% |
* Healthcare Sector Average
HIND
Vyome Holdings
2.09
-39.96
-95.03%
SINT
Sintx Technologies
2.42
-0.29
-10.70%
HSDT
Solana Company
2.16
-228.84
-99.06%
MOVE
Movano
13.10
6.55
99.91%
HSCS
Heart Test Laboratories, Inc.
2.04
-1.42
-41.04%
Vyome Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Vyome Holdings Shareholders Tighten Capital Structure at Meeting
Positive
Apr 29, 2026
At Vyome Holdings’ 2026 Annual Meeting of Stockholders held on April 24, 2026, shareholders representing roughly 65.57% of eligible common shares were present in person or by proxy, providing a quorum for key governance decisions. Investors ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics
Positive
Feb 25, 2026
On February 20, 2026, Vyome’s subsidiary Livechain, Inc. and its unit LICH AI Inc. entered into a Notes Purchase and Exchange Agreement with Remus Capital to acquire $5.77 million in senior secured convertible notes of Sociometric Solutions,...
Business Operations and StrategyProduct-Related Announcements
Vyome Reports Positive Phase 2 Data for VT-1953 Gel
Positive
Feb 13, 2026
Vyome Holdings reported Phase 2 investigator-sponsored trial results for VT-1953, a 2% topical gel for malignant fungating wounds, demonstrating statistically significant reductions in malodor by Day 14 versus both baseline and vehicle, with 80% o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.